Alembic Pharmaceuticals: Unaudited Financial Results for the Quarter and Half Year ended 30th September, 2026
Alembic Pharmaceuticals (APLLTD) filed a disclosure titled "Unaudited Financial Results for the Quarter and Half Year ended 30th September, 2026". The company is valued at about ₹18,936 crore.
What happened
Alembic Pharmaceuticals (APLLTD) filed a disclosure with the exchanges on 4 November 2026 at 02:26 PM titled "Unaudited Financial Results for the Quarter and Half Year ended 30th September, 2026".
Company snapshot
Alembic Pharmaceuticals is a small-cap company in the Healthcare sector, with a market value of about ₹18,936 crore.
The stock last traded at ₹963.4, against a 52-week range of ₹635.8–₹998 (3.5% below the high).
Before this filing the shares had moved −1.5% over the month and −0.8% over three months. Average daily turnover over the last 20 sessions was about ₹8.65 crore.
Promoters held 69.87% at the end of Q1 FY27, up 0.13% points from the previous quarter. Foreign institutions owned 4.18% and domestic institutions 15.94%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 1,711 | 154.4 | 7.85 |
| Q2 FY26 | 1,910 | 184.7 | 9.4 |
| Q3 FY26 | 1,876 | 133 | 6.76 |
| Q4 FY26 | 1,848 | 201.5 | 10.31 |
| Q1 FY27 | 2,150 | 173.1 | 8.8 |
What history shows
BCEIE's records show 3 previous results filings from the company since May 2026.
After those filings, the stock gained 1.6% on average the next trading day and was up 4.1% on average after five days (2 filings with price data).
Across 300 similar disclosures by other Healthcare companies, shares moved +1.4% on average the next day and +1.9% over five days; 57% of them rose the next day.
Market-wide, 10,609 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 4 Aug 2026 | A press release dated August 04, 2026, titled "Press Release on the… | +1.5% | +4.1% |
| 4 Aug 2026 | , the financial results for the period ended Jun 30, 2026. | +1.5% | +4.1% |
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 4 November 2026: Board meeting — Financial Results/Other business matters.
In the news
Recent coverage elsewhere (links open the original publisher):
- Alembic Pharmaceuticals Limited Estimates – NSE:APLLTD
- Pradeep Jain Appointed Associate Vice President – Accounts & Finance at Alembic Pharmaceuticals
- Alembic Pharmaceuticals Receives USFDA Approval for Venetoclax Tablets
- Alembic Pharmaceuticals Limited (APLLTD.NS) Seasonal returns chart
- Alembic Pharmaceuticals receives USFDA final approval for Venetoclax tablets
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.